16 October 2024 US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity.
Madrigal Pharmaceuticals, a US biopharma pursuing new therapeutics for non-alcoholic steatohepatitis (NASH), has announced the pricing of its underwritten public offering. 2 October 2023
US health technology assessor the Institute for Clinical and Economic Review (ICER) today posted a Special Report evaluating the evidence on Eliquis (apixaban) and Xarelto (rivaroxaban) for the treatment of non-valvular atrial fibrillation (NVAF). 2 October 2023
Swiss pharma giant Novartis has announced positive top-line results from the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study at nine months. 2 October 2023
ModeX Therapeutics, an OPKO Health company, has received a sizeable grant of up to $168 million from the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Administration for Strategic Preparedness and Response at the US Department of Health and Human Services. 2 October 2023
Addressing what has been dubbed the ‘triple A’ challenge of access, affordability and availability has been an objective of the European Medicines Agency (EMA) for nearly 30 years, going back to the launch of the centralized procedure in 1995. 29 September 2023
Israel and USA-based artificial intelligence (AI) company Quris-AI says that it has agreed to expand its existing partnership with Germany’s Merck KGaA. 29 September 2023
US financial services company Morningstar has published its Biopharma Pipeline Report which provides a five-year outlook on key trends in the space, as well as an in-depth review of pipelines and major therapeutic areas. 29 September 2023
The UK pharma industry has responded to proposed changes to the statutory scheme for branded medicines, arguing against their implementation. 29 September 2023
Karuna Therapeutics has taken a significant step with its submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for KarXT (xanomeline-trospium), its ground-breaking product aiming to revolutionize the treatment of schizophrenia. 28 September 2023
Ophthalmic company Ocuphire Pharma, a specialist in retinal and refractive eye disorders, together with partner Viatris, have secured US approval for Ryzumvi (phentolamine). 27 September 2023
US biopharma Soleno Therapeutics saw its market capitalization leap five-fold yesterday, with the shares hitting $26.80, after it announced promising research results for its lead pipeline candidate, which has encountered previous setbacks. 27 September 2023
USA-based Ionis Pharmaceuticals yesterday released positive top-line results for the Phase III Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS), a rare genetic disorder. 27 September 2023
Molnupiravir, an antiviral treatment for COVID-19 marketed by US pharma giant Merck & Co under the name Lagevrio, could in fact lead to the virus mutating, according to a research article. 26 September 2023
A $250 million private financing for California’s BridgeBio Pharma will support a possible launch of acoramidis, as well as further late-stage pipeline development. 26 September 2023
Australian dermatology company Botanix today revealed it has received a communication from the US Food and Drug Administration (FDA) in relation to its New Drug Application (NDA) submission for sofpironium bromide (SB) gel, 15%. 26 September 2023
Danish company Acesion Pharma has closed an oversubscribed Series B financing round, raising around 43 million euros ($48 million) to support its work in atrial fibrillation (AF). 26 September 2023
Danish drugmaker Novo Nordisk and Valo Health have entered into an agreement to discover and develop novel treatments for cardiometabolic diseases. 25 September 2023
Research is repeatedly showing that co-administration of individual drugs as combination therapy offers significant benefits to patients. 25 September 2023
Continuing its recent strong investment in the area of oncology, French privately-held company Pierre Fabre has inked a new drug discovery deal with British firm Vernalis. 25 September 2023
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.